Leerink Partnrs Increases Earnings Estimates for Genmab A/S

Genmab A/S (NASDAQ:GMAB) – Investment analysts at Leerink Partnrs lifted their FY2025 earnings per share estimates for shares of Genmab A/S in a research note issued to investors on Thursday, May 8th. Leerink Partnrs analyst J. Chang now expects that the company will earn $1.68 per share for the year, up from their prior estimate of $1.59. Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for Genmab A/S’s current full-year earnings is $1.45 per share. Leerink Partnrs also issued estimates for Genmab A/S’s Q4 2025 earnings at $0.62 EPS and FY2026 earnings at $1.98 EPS.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings results on Thursday, May 8th. The company reported $0.31 EPS for the quarter, beating analysts’ consensus estimates of $0.23 by $0.08. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. The company had revenue of $715.00 million during the quarter, compared to analysts’ expectations of $5.17 billion.

GMAB has been the subject of a number of other reports. William Blair upgraded Genmab A/S from a “market perform” rating to an “outperform” rating in a report on Tuesday, March 11th. HC Wainwright restated a “buy” rating and issued a $37.00 price objective (down from $50.00) on shares of Genmab A/S in a report on Wednesday, April 9th. Sanford C. Bernstein downgraded Genmab A/S from a “market perform” rating to an “underperform” rating in a report on Tuesday, April 1st. Truist Financial decreased their price objective on Genmab A/S from $50.00 to $45.00 and set a “buy” rating for the company in a report on Tuesday, March 11th. Finally, Leerink Partners upgraded Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 price objective for the company in a report on Thursday, February 13th. One analyst has rated the stock with a sell rating, three have given a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $39.17.

Genmab A/S Stock Performance

Shares of GMAB opened at $19.93 on Monday. Genmab A/S has a 52 week low of $17.24 and a 52 week high of $30.41. The stock has a market capitalization of $12.78 billion, a price-to-earnings ratio of 11.45, a PEG ratio of 2.65 and a beta of 1.04. The stock has a fifty day moving average of $19.99 and a 200-day moving average of $20.84.

Institutional Trading of Genmab A/S

A number of large investors have recently bought and sold shares of the business. Deep Track Capital LP acquired a new stake in Genmab A/S during the 4th quarter worth about $41,740,000. Renaissance Technologies LLC grew its stake in shares of Genmab A/S by 7.8% in the 4th quarter. Renaissance Technologies LLC now owns 1,926,150 shares of the company’s stock valued at $40,199,000 after buying an additional 139,722 shares during the period. Two Sigma Investments LP grew its stake in shares of Genmab A/S by 122.2% in the 4th quarter. Two Sigma Investments LP now owns 1,706,364 shares of the company’s stock valued at $35,612,000 after buying an additional 938,455 shares during the period. Two Sigma Advisers LP grew its stake in shares of Genmab A/S by 168.8% in the 4th quarter. Two Sigma Advisers LP now owns 1,653,500 shares of the company’s stock valued at $34,509,000 after buying an additional 1,038,400 shares during the period. Finally, First Trust Advisors LP grew its stake in shares of Genmab A/S by 18.0% in the 4th quarter. First Trust Advisors LP now owns 1,644,288 shares of the company’s stock valued at $34,316,000 after buying an additional 251,241 shares during the period. 7.07% of the stock is currently owned by institutional investors and hedge funds.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.